New cell therapy aims to make risky cancer transplants safer

This early-stage trial is testing whether adding specially treated immune cells, called 'veto cells,' can help patients with blood cancers or bone marrow disorders after a stem cell transplant from a half-matched donor. The goal is to help the donor's cells grow and work in the patient's body while reducing the risk of a dangerous complication where the donor cells attack the patient's own tissues. Researchers are studying the safety of these cells and finding the best dose for future studies.